VIRGINIA RETIREMENT SYSTEMS ET Al raised its holdings in Haemonetics Corporation (NYSE:HAE – Free Report) by 178.6% during the third quarter, HoldingsChannel reports. The firm owned 11,700 shares of the medical instruments supplier’s stock after acquiring an additional 7,500 shares during the quarter. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in Haemonetics were worth $1,232,000 at the end of the most recent reporting period.
Several other institutional investors have also recently bought and sold shares of the business. Dimensional Fund Advisors LP lifted its holdings in shares of Haemonetics by 21.3% in the first quarter. Dimensional Fund Advisors LP now owns 1,326,057 shares of the medical instruments supplier’s stock worth $74,731,000 after acquiring an additional 233,119 shares during the last quarter. Assenagon Asset Management S.A. grew its stake in shares of Haemonetics by 1,191.9% during the third quarter. Assenagon Asset Management S.A. now owns 453,579 shares of the medical instruments supplier’s stock worth $47,762,000 after buying an additional 418,470 shares during the last quarter. Bank of America Corp DE bought a new stake in shares of Haemonetics during the second quarter worth $33,326,000. William Blair Investment Management LLC acquired a new position in Haemonetics in the 2nd quarter worth about $24,906,000. Finally, Bank of New York Mellon Corp acquired a new position in Haemonetics in the 2nd quarter valued at approximately $21,566,000. Institutional investors and hedge funds own 99.67% of the company’s stock.
Analyst Ratings Changes
A number of research firms have recently commented on HAE. Citigroup upped their price objective on shares of Haemonetics from $79.00 to $92.00 and gave the company a “neutral” rating in a research note on Friday, August 7th. BTIG Research lifted their target price on shares of Haemonetics from $110.00 to $130.00 and gave the stock a “buy” rating in a research note on Thursday, October 8th. JPMorgan Chase & Co. boosted their target price on shares of Haemonetics from $62.00 to $86.00 and gave the company a “neutral” rating in a report on Friday, August 7th. Raymond James Financial upped their price target on shares of Haemonetics from $105.00 to $125.00 and gave the company an “outperform” rating in a research report on Thursday, September 3rd. Finally, Robert W. Baird increased their price target on Haemonetics from $96.00 to $119.00 and gave the stock an “outperform” rating in a report on Friday, August 21st. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, Haemonetics has a consensus rating of “Moderate Buy” and an average price target of $110.00.
Read Our Latest Analysis on HAE
Haemonetics Stock Performance
Shares of HAE opened at $127.40 on Thursday. Haemonetics Corporation has a one year low of $49.96 and a one year high of $128.83. The company has a market cap of $5.80 billion, a PE ratio of 62.45, a P/E/G ratio of 2.40 and a beta of 0.63. The stock has a 50-day moving average of $110.86 and a 200-day moving average of $79.55. The company has a debt-to-equity ratio of 1.40, a current ratio of 3.08 and a quick ratio of 1.91.
Haemonetics (NYSE:HAE – Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $1.14 earnings per share for the quarter, topping analysts’ consensus estimates of $1.08 by $0.06. The business had revenue of $339.38 million for the quarter, compared to the consensus estimate of $327.86 million. Haemonetics had a return on equity of 27.55% and a net margin of 7.12%. The firm’s revenue for the quarter was up 5.5% on a year-over-year basis. During the same period in the prior year, the business earned $1.10 EPS. On average, equities research analysts predict that Haemonetics Corporation will post 5.29 EPS for the current fiscal year.
About Haemonetics
Haemonetics Corporation (NYSE: HAE) is a healthcare technology company that develops and supplies products and services for blood and plasma collection, processing, and management. Its solutions are used by blood and plasma collection organizations, hospitals, and other healthcare providers to support the efficient handling of blood components and improve patient care.
The company’s offerings include automated plasma and blood-component collection systems, disposable collection sets, blood-processing equipment, and software designed to manage collection and transfusion-related operations.
Further Reading
- Five stocks we like better than Haemonetics
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Corporation (NYSE:HAE – Free Report).
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
